

# Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Diclofenac Sodium and Diclofenac Potassium

B. CHUASUWAN,<sup>1,2</sup> V. BINJESOH,<sup>1,3</sup> J.E. POLLI,<sup>1</sup> H. ZHANG,<sup>4</sup> G.L. AMIDON,<sup>5</sup> H.E. JUNGINGER,<sup>6</sup> K.K. MIDHA,<sup>7</sup> V.P. SHAH,<sup>9</sup> S. STAVCHANSKY,<sup>9</sup> J.B. DRESSMAN,<sup>10</sup> D.M. BARENDS<sup>11</sup>

<sup>1</sup>Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland

<sup>2</sup>Research and Development Institute, The Government Pharmaceutical Organization, Bangkok, Thailand

<sup>3</sup>Faculty of Pharmacy, Rangsit University, Pathumtani, Thailand

<sup>4</sup>AstraZeneca Pharmaceuticals LP, Wilmington, Delaware

<sup>5</sup>College of Pharmacy, University of Michigan, Ann Arbor, Michigan

<sup>6</sup>Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

<sup>7</sup>University of Saskatchewan, Saskatoon, Saskatchewan, Canada

<sup>8</sup>International Pharmaceutical Federation FIP, The Hague, The Netherlands

<sup>9</sup>Pharmaceutical Division, College of Pharmacy, University of Texas at Austin, Austin, Texas

<sup>10</sup>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt, Germany

<sup>11</sup>RIVM—National Institute for Public Health and the Environment, Bilthoven, The Netherlands

Received 23 May 2008; accepted 3 July 2008

Published online 27 August 2008 in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.21525

**ABSTRACT:** Literature data are reviewed regarding the scientific advisability of allowing a waiver of *in vivo* bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing either diclofenac potassium and diclofenac sodium. Within the biopharmaceutics classification system (BCS), diclofenac potassium and diclofenac sodium are each BCS class II active pharmaceutical ingredients (APIs). However, a biowaiver can be recommended for IR drug products of each salt form, due to their therapeutic use, therapeutic index, pharmacokinetic properties, potential for excipient interactions, and performance in reported BE/bioavailability (BA) studies, provided: (a) test and comparator contain the same diclofenac salt; (b) the dosage form of the test and comparator is identical; (c) the test product contains only excipients present in diclofenac drug products approved in ICH or associated countries in the same dosage form, for instance as presented in this paper; (d) test drug product and comparator dissolve 85% in 30 min or less in 900 mL buffer pH 6.8, using the paddle apparatus at 75 rpm or the basket apparatus at 100 rpm; and (e) test product and comparator show dissolution profile similarity in pH 1.2, 4.5, and 6.8. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association *J Pharm Sci* 98:1206–1219, 2009

A project of the International Pharmaceutical Federation FIP, Groupe BCS, www.fip.org/bcs. This article reflects the scientific opinion of the authors and not the policies of regulating agencies, the International Pharmaceutical Federation (FIP) and the World Health Organization (WHO).

Correspondence to: D.M. Barends (Telephone: 31-30-2744209; Fax: 31-30-2744462; E-mail: dirk.barends@rivm.nl)

*Journal of Pharmaceutical Sciences*, Vol. 98, 1206–1219 (2009)

© 2008 Wiley-Liss, Inc. and the American Pharmacists Association

**Keywords:** absorption; bioequivalence; biopharmaceutics classification system (BCS); diclofenac; permeability; solubility; regulatory science

## INTRODUCTION

A biowaiver monograph of diclofenac is presented based on literature data and new experimental data. Risks are evaluated in basing a BE assessment on *in vitro* study results (i.e., “biowaiving”), rather than *in vivo* study results, for the approval of new IR solid oral dosage forms containing diclofenac sodium and diclofenac potassium, for example, plain IR tablets, dispersible tablets and powders for oral solutions. This risk evaluation considers diclofenac sodium and diclofenac potassium biopharmaceutical and clinical properties, as they pertain to reformulated products and new multisource products. This evaluation concerns drug products containing diclofenac as the only API and does not concern combination drug products. This evaluation does not concern delayed release products or any other modified release formulations of diclofenac.

The purpose and scope of this series of monographs have been previously discussed.<sup>1</sup> Briefly, the aim is to evaluate all pertinent data available from literature sources for a given API to assess the risks associated with a biowaiver. For these purposes, risk is defined as the probability of making an incorrect biowaiver decision, as well as the resulting consequences of such a decision in terms of public health and individual patient risks. On the basis of these considerations, a recommendation can be made as to whether a biowaiver is advisable or not. This systematic approach to recommend for or to advise against a biowaiver is described in the recently published World Health Organization (WHO) Guideline.<sup>2</sup> These monographs do not intend to simply apply the WHO, FDA<sup>3</sup> and/or EMEA Guidance,<sup>4</sup> but aim to apply these guidances and further serve as a critical validation of these regulatory documents. Biowaiver monographs have already been published for acetaminophen (INN: paracetamol),<sup>5</sup> acetazolamide,<sup>6</sup> aciclovir,<sup>7</sup> amitriptyline,<sup>8</sup> atenolol,<sup>1</sup> chloroquine,<sup>9</sup> cimetidine,<sup>10</sup> ethambutol,<sup>11</sup> ibuprofen,<sup>12</sup> isoniazid,<sup>13</sup> metoclopramide, prednisolone,<sup>14</sup> prednisone,<sup>15</sup> pyrazinamide,<sup>16</sup> propranolol,<sup>1</sup> ranitidine,<sup>17</sup> and verapamil.<sup>1</sup> They are also available on-line at [www.fip.org/bcs](http://www.fip.org/bcs). Although diclofenac is not on the present WHO List of

Essential Medicines,<sup>18</sup> it was considered appropriate to include this widely used and important API in this series.

## Literature Review

Published information was obtained from PubMed up to November 2007. Key words used were: diclofenac potassium, diclofenac sodium, NSAID, indication, therapeutic index, solubility, polymorphism, partition coefficient,  $pK_a$ , absorption, permeability, distribution, metabolism, excretion, excipients, bioequivalence and dissolution.


## GENERAL CHARACTERISTICS

### Name and Structure

The chemical name of diclofenac is 2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid. Its structure is shown in Figure 1.

### Therapeutic Indication, Side Effect and Therapeutic Index

Diclofenac is a well-known nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties, comparable or superior to other NSAIDs.<sup>19</sup> Diclofenac shows preferential inhibition of the cyclooxygenase-2



**Figure 1.** Structure of diclofenac, where M = K<sup>+</sup> or Na<sup>+</sup> for potassium or sodium salt, respectively.

(COX-2) enzyme.<sup>20</sup> Diclofenac sodium is mainly indicated in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Diclofenac potassium is claimed to dissolve faster, and hence absorbed faster, than the sodium salt and is recommended for the treatments that need short onset of action, mainly for its analgesic properties. Diclofenac potassium is also indicated for the treatment of primary dysmenorrhea and mild to moderate pain.<sup>21,22</sup> As with other NSAIDs, diclofenac is known to increase the risk of gastrointestinal bleeding and cardiovascular side effects.<sup>21,22</sup> However, diclofenac has a relatively high therapeutic index in comparison to other NSAIDs.<sup>23</sup>

## PHYSICOCHEMICAL PROPERTIES

### Salts, Esters, Polymorphs, Hydrates

Diclofenac is usually formulated as the sodium or potassium salt, but other salts are also used, such as hydroxyethylpyrrolidine salt for oral preparations, and diethylammonium and diethylamine for topical preparation.<sup>24</sup> This monograph refers to drug products containing the sodium or potassium salt of diclofenac only. Most "plain" tablets contain the potassium salt, whereas most dispersible dosage forms contain diclofenac sodium, see Tables 1 and 2. In this monograph, the term diclofenac without indicating the salt form refers to the sodium and potassium salts. Trihydrates and tetrahydrates exist for both of diclofenac potassium and diclofenac sodium,<sup>25,26</sup> but in pharmacopoeial drug products only the anhydrate is used.<sup>27,28</sup>

### Solubility

Solubility values for diclofenac sodium taken from the literature<sup>29</sup> are shown in Table 3 and experimentally determined solubilities of diclofenac potassium are shown in Table 4, respectively, together with the dose to solubility ratios ( $D/S$ ) for several tablet strengths.

### Polymorphism

Reports of diclofenac potassium or diclofenac sodium polymorphs were not found in the literature.

### Partition Coefficient

Partition coefficient in *n*-octanol/aqueous buffer ( $\log D$ ) are reported to be 1.4 and 1.1 for pH 6.8 and

7.4, respectively.<sup>30–32</sup> The experimental  $\log P$  (*n*-octanol/water) and  $C \log P$  values of diclofenac are 4.40 and 4.71, respectively,<sup>33,34</sup> which are larger than the corresponding values of 1.72 and 1.35 for the highly permeable marker drug metoprolol.<sup>35</sup>

### $pK_a$

The  $pK_a$  of diclofenac is about 3.80 at 25°C.<sup>36,37</sup>

## Strengths of Marketed Drug Products

Dosage form strength is expressed in mg of salt present, not equivalent of the free acid. In the United States (US) and in the EU, Marketing Authorizations (MAs), that is, registrations, exist for IR solid oral dosage forms for 12.5, 25, and 50 mg diclofenac salt, see Tables 1 and 2. Higher strengths of these drugs have been marketed, but only as delayed release solid forms or combination oral products; however, such products are outside the scope of this monograph.

## PHARMACOKINETIC PROPERTIES

The majority of pharmacokinetic data concerns diclofenac sodium. Literature reports indicate that diclofenac sodium and diclofenac potassium are similar in terms of extent of oral absorption, pattern of distribution, metabolism, and elimination.<sup>38</sup>

### Absorption and Permeability

Diclofenac is 100% absorbed after oral administration, compared to intravenous administration, based on urine recovery studies.<sup>21,22</sup> Only about 60% of drug reaches the systemic circulation due to first pass metabolism.<sup>39,40</sup> In some fasting volunteers, measurable plasma levels are observed within 10 min of dosing with diclofenac potassium, although peak plasma levels are generally achieved after 0.33–2 h.<sup>21</sup> For enteric-coated diclofenac sodium tablets, drug is released once the tablet reaches the duodenum, with subsequent rapid absorption.<sup>30,41,42</sup> Absorption of diclofenac occurs throughout the intestinal tract.<sup>43–46</sup> Diclofenac shows linear pharmacokinetics. The absolute BA of diclofenac potassium after oral administration did not differ significantly when 1 × 12.5- and 2 × 12.5-mg were dose in a randomized, three-way, crossover study in

**Table 1.** Excipients<sup>a</sup> Present in Diclofenac<sup>b</sup> IR Solid Oral Drug Products<sup>c</sup> With a Marketing Authorization (MA) in Germany (DE), Denmark (DK), Finland (FI), France (FR), The Netherlands (NL), Norway (NO), Spain (ES), Sweden (SE), United Kingdom (UK) and the United States (US)<sup>d</sup>, and the Minimal and Maximal Amount of that Excipient Present Pro Dosage Unit in Solid Oral Drug Products With an MA in the USA<sup>e</sup>

| Excipient                    | Drug Products Containing that Excipient With an MA Granted by the Named Country  | Range Present in Solid Oral Dosage Forms With an MA in the USA (mg) |
|------------------------------|--|---|
| Benzoic acid                 | DK(1) NO(2) SE(3)  | No data   |
| Calcium hydrogen phosphate   | DE(4) DK(5–12) FI(13,14) NO(15,16) SE (17,18) UK(19)   | 104–850   |
| Calcium phosphate            | DE(20) DK(21) FI(22) NL(23) NO(24) SE (25,26) US(27,28)  | 21–362  |
| Carmellose sodium            | DK(29) FI(30) NO(31) SE (32)   | 2.2–160   |
| Cellulose                    | DE(20,33–36) DK(1,29,37) ES(38,39) FI(30,40)<br>FR (41) NL(23,42,43) NO(2,31,44,45) SE<br>(3,25,26,32,46,47) US(27,28,48,49)   | 4.6–1385 <sup>f</sup>   |
| Croscarmellose sodium        | FI(40) US (48)   | 2–180   |
| Crospovidone                 | DE(50,51)  | 4.4–792 <sup>f</sup>  |
| dimeticone                   | DE(33)   | 3.7   |
| Glycerol                     | DK(29) FI(30,40) NO(31) SE (32)  | 0.14–198 <sup>f</sup>   |
| Glycerol dibehenate          | DE(50,51)  | 5.7–14  |
| Hypromellose                 | DE(34–36,50,51) DK(1,29,37) ES(38) FI(30,40) FR<br>(41) NO(2,31) SE (3,32) US (28,48)  | 0.8–86  |
| Lactose                      | DE(34–36) DK(1,29,37) ES(38,39) FI(30,40) FR (41)<br>NL(42,43) NO(2,31,44,45) SE (3,32,46,47) US (28,48,49)  | 23–1020 <sup>f</sup>  |
| Lecithin                     | DE(4) DK(5–12) FI(13,14) NO(15,16) SE (17,18)  | 5–15  |
| Macrogol                     | DE(20,33–36,50,51) DK(1,37) ES(38) FR (41) NL(23) NO(2)<br>SE (3,25,26) US (27,28,48)  | 0.12–500 <sup>f</sup>   |
| Macrogol stearate            | DK(1) NO(2) SE (3)   |   |
| Magnesium stearate           | DE(4,20,33–36,50,51) DK(1,5–12,21,29,37) ES(38,39)<br>FI(13,14,22,30,40) FR (41) NL(23,42,43) NO(2,15,16,<br>24,31,44,45) SE (3,17,18,25,26,32,46,47) UK(19) US<br>(27,28,48,49) | 0.15–401 <sup>f</sup>   |
| Maltodextrin                 | DE(35,36) DK(37) FR (41)   | 0.16–80   |
| Mannitol                     | DE(50,51)  | 33–454  |
| Octamethylcyclotetrasiloxane | DK(1) NO(2) SE (3)   | No data   |
| Polydextrose                 | US (48)  | 3.8–8.1   |
| Polysorbate <sup>g</sup>     | DK(37)   | No data   |
| Polysorbate 80               | DE(35,36) FR (41)  | 2.2–418 <sup>f</sup>  |
| Poly(vinylalcohol)           | DE(4) DK(5–8) FI(13,14) NO(15,16) SE (17,18)   | 0.7–20  |
| Potassium hydrogen carbonate | DE(50,51)  | 12  |
| Povidone                     | DE(4,20,33–36) DK(5–12,21,37) ES(38,39) FI(13,14,22) FR (41)<br>NL(23,42,43) NO(15,16,24,44,45) SE(17,18,25,26,46,47)<br>UK (19) US (27,28)                                      | 0.17–75   |
| Silica                       | DE(4,20,34–36) DK(5–12,21,29,37) ES(38,39) FI(13,<br>14,22,30,40) FR (41) NL(23,42,43) NO(15,16,24,31,44,45) SE<br>(17,18,25,26,32,46,47) UK (19) US (27,28,48)                  | 0.65–99   |
| Simethicone                  | DK(1) NO(2) SE (3)   | 0.0004–5.7  |
| Sodium hydroxide             | DE(33)   | 0.74–6.7  |
| Sodium lauryl sulphate       | DE(50,51) US (48)  | 0.65–50   |
| Sodium starch glycolate      | DE(4,20,33,35,36) DK(1,5–12,21,37) ES(38,39) FI(13,14,22)<br>FR (41) NL(23,42,43) NO(2,15,16,24,44,45) SE<br>(3,17,18,25,26,46,47) UK (19) US (27,28)                            | 2–876 <sup>f</sup>  |
| Sorbic acid                  | DK(1) NO(2) SE (3)   | 0.94  |

(Continued)

**Table 1.** (Continued)

| Excipient              | Drug Products Containing that Excipient With an MA Granted by the Named Country   | Range Present in Solid Oral Dosage Forms With an MA in the USA (mg) |
|------------------------|---|---|
| Starch                 | DE(4,20,33–36) DK(1,5–12,21,29,37) ES(38,39)<br>FI(13,14,22,30,40) FR (41) NL(23,42,43)<br>NO(2,15,16,24,31,44,45) SE (3,17,18,25,26,32,46,47)<br>UK(19) US (27,28) | 0.44–1135 <sup>f</sup>  |
| Starch, pregelatinized | US (49)   | 6.6–600   |
| Sucrose                | DE(20,33) NL(23) SE (25,26) US (27)   | 12–900  |
| Talc                   | DE(4,20,33,34) DK(1,5–12) ES(38) FI(13,14) NL(23)<br>NO(2,15,16) SE (3,17,18,25,26)   | 0.26–220 <sup>f</sup>   |
| Triacetin              | US (48)   | 0.72–15   |
| Xanthan gum            | DE(4) DK(5–12) FI(13,14) NO(15,16) SE (17,18)   | 14  |
| 1.                     | Eeze, fillovertrukne tabletter  |   |
| 2.                     | Ezze 25 mg filmdrasjerte tabletter  |   |
| 3.                     | Eeze 25/50 mg, filmdragerade tabletter  |   |
| 4.                     | Diclac <sup>®</sup> Dolo 12.5 mg Filmtabletten (Mono)   |   |
| 5.                     | Diclofenac Rapid “Actavis”, fillovertrukne tabletter  |   |
| 6.                     | Diclofenac Rapid “Copyfarm”, fillovertrukne tabletter   |   |
| 7.                     | Diclone Rapid, fillovertrukne tabletter   |   |
| 8.                     | Diclopax, fillovertrukne tabletter  |   |
| 9.                     | Fenaclo, fillovertrukne tabletter   |   |
| 10.                    | Dictavis, fillovertrukne tabletter  |   |
| 11.                    | Dicium, fillovertrukne tabletter  |   |
| 12.                    | Fenacta, fillovertrukne tabletter   |   |
| 13.                    | Diclofenac Rapid Actavis 25/50 mg tabletti, kalvopäällysteinen  |   |
| 14.                    | Diclofenac Rapid Copyfarm 25/50 mg tabletti, kalvopäällysteinen   |   |
| 15.                    | Diclofenackalium Actavis 25/50 mg tabletter, filmdrasjerte  |   |
| 16.                    | Diclofenackalium Copyfarm 25/50 mg filmdrasjerte tabletter  |   |
| 17.                    | Diklofenak T Actavis 25/50 mg filmdragerade tabletter   |   |
| 18.                    | Diklofenak T Copyfarm 25 mg och 50 mg filmdragerade tabletter   |   |
| 19.                    | Diclofenac potassium 12.5 mg tablets  |   |
| 20.                    | Voltaren <sup>®</sup> K Migräne 50 mg überzogene Tabletten (Mono)   |   |
| 21.                    | Voltaren Rapid, overtrukne tabletter  |   |
| 22.                    | Voltaren Rapid 25/50 mg tabletti, päällystetty  |   |
| 23.                    | Cataflam 25/50, omhulde tabletten 25/50 mg  |   |
| 24.                    | CATAFLAM 50 mg drasjerte tabletter  |   |
| 25.                    | Diklofenak T Sandoz 25/50 mg, tabletter   |   |
| 26.                    | Voltaren T 25/50 mg, dragerade tabletter  |   |
| 27.                    | Cataflam <sup>®</sup> tablet 50 mg, sugar-coated [Novartis Pharmaceuticals Corporation]   |   |
| 28.                    | Diclofenac potassium tablets 50 mg, film-coated [TEVA Pharmaceuticals USA]  |   |
| 29.                    | Diclofenac ratiopharm Rapid, fillovertrukne tabletter   |   |
| 30.                    | Diclomex Rapid 25/50 mg tabletti, kalvopäällysteinen  |   |
| 31.                    | DiclofenacKalium ratiopharm tabletter, filmdrasjert   |   |
| 32.                    | Diclofenac T ratiopharm 25/50 mf filmdragerade tabletter  |   |
| 33.                    | Diclofenac PB 50 mg Tabletten (Mono) <sup>h</sup>   |   |
| 34.                    | Diclodoc <sup>®</sup> 50 Tabletten (Mono) <sup>h</sup>  |   |
| 35.                    | Optalidon <sup>®</sup> Zahnschmerz mit Diclofenac Filmtabletten (Mono)  |   |
| 36.                    | Voltaren <sup>®</sup> Dolo 12. mg Filmtabletten (Mono)  |   |
| 37.                    | Voltaren Dolo, fillovertrukne tabletter   |   |
| 38.                    | DICLOFENACO PENSA 50 mg comprimidos EFG <sup>h</sup>  |   |
| 39.                    | Voltalgial 12.5 mg comprimidos  |   |

(Continued)

**Table 1.** (Continued)

| Excipient | Drug Products Containing that Excipient With an MA Granted by the Named Country  | Range Present in Solid Oral Dosage Forms With an MA in the USA (mg) |
|-----------|--|---|
| 40.       | Diclofenac Rapid ratiopharm 25/50 mg tabletti, kalvopäällysteinen                |   |
| 41.       | VOLTARENDOLO 12.5 mg cp enr  |   |
| 42.       | Voltaren K, omhulde tabletten 12.5 mg  |   |
| 43.       | Otriflu, omhulde tabletten 12.5 mg   |   |
| 44.       | CATAFLAM 12.5 mg tabletter, filmdrasjerte  |   |
| 45.       | Otriflu 12.5 mg tabletter, filmdrasjerte   |   |
| 46.       | Otriflu 12.5 mg filmdragerade tabletter  |   |
| 47.       | Voltaren T 12.5 mg filmdragerade tabletter                                       |   |
| 48.       | Diclofenac potassium tablets USP, 50 mg film-coated [Mylan Pharmaceuticals Inc.] |   |
| 49.       | Diclofenac potassium tablets 50 mg, film-coated [Sandoz Inc.]                    |   |
| 50.       | Diclo-CT akut 12.5 mg Filmtabletten (Mono)                                       |   |
| 51.       | Diclofenac-ratiopharm <sup>®</sup> Schmerztabletten 12.5 mg Filmtabletten (Mono) |   |

<sup>a</sup>Colourants, flavors and ingredients present in the printing ink are not included. Coating substances are excluded if in the SmPC the constituents of core and coating are stated separately.

<sup>b</sup>Diclofenac potassium and diclofenac sodium. Unless otherwise indicated the reported drug products contain diclofenac potassium.

<sup>c</sup>Drug products containing more than one API are excluded. Soluble tablets, dispersible tablets and powders and tablets to prepare an oral solution are reported in Table 2.

<sup>d</sup>Sources of data: DE, [www.rote-liste.de](http://www.rote-liste.de) (assessed September 25, 2007); DK, [www.dkma.dk](http://www.dkma.dk) (assessed September 20, 2007); FI, [www.nam.fi](http://www.nam.fi) (assessed September 25, 2007); FR, [www.vidal.fr](http://www.vidal.fr) (assessed September 24, 2007); NL, [www.cbg-meb.nl](http://www.cbg-meb.nl) (assessed September 20, 2007); NO, [www.legemiddelverket.no](http://www.legemiddelverket.no) (assessed September 24, 2007); ES, [www.agemed.es](http://www.agemed.es) (assessed September 21, 2007); SE, [www.lakemedelsverket.se](http://www.lakemedelsverket.se) (assessed September 25, 2007); UK, [www.mhra.gov.uk](http://www.mhra.gov.uk) (assessed February 7, 2008); USA, <http://dailymed.nlm.nih.gov> (assessed February 6, 2008).

<sup>e</sup>FDA's Inactive Ingredient Database: <http://www.fda.gov/cder/iig/iigfaqweb.htm#purpose> (version date November 1, 2007).

<sup>f</sup>The reported upper range value is unusually high. The authors doubt its correctness.

<sup>g</sup>Without specified grade.

<sup>h</sup>Contains diclofenac sodium.

10 subjects.<sup>39</sup> The systemic absorption of diclofenac as a function of the dose is proportional within the range 25–150 mg,<sup>39,44</sup> which suggests that the low drug solubility at low pH is not limiting absorption.

Administration with food can extend the lag time ( $t_{lag}$ ) of drug absorption, thereby increasing the time to maximum concentration ( $t_{max}$ ) and decreasing the maximum concentration ( $C_{max}$ ). Food does not have a significant effect on the extent of oral absorption of diclofenac sodium or diclofenac potassium.<sup>22,38,47,48</sup> Diclofenac's rapid and complete absorption suggests a high permeability through the intestinal membrane.<sup>43,44</sup> This observation of high permeability throughout the intestinal tract is also supported by reports of rapid absorption of diclofenac from effervescent tablets<sup>45</sup> and the high permeability of diclofenac in the colon after administration of the drug as a suppository.<sup>46</sup>

In a Caco-2 cell monolayer experiment, the permeability of diclofenac from apical-to-basolateral ( $P_{A-B}$ ) and basolateral-to-apical ( $P_{B-A}$ ) direc-

tions were  $20.2 \times 10^{-6}$  and  $21.3 \times 10^{-6}$  cm/s, respectively, while metoprolol permeability was  $43.4 \pm 0.7 \times 10^{-6}$  and  $34.1 \pm 0.6 \times 10^{-6}$  cm/s in the two directions, respectively.<sup>49</sup> Metoprolol is 90–95% absorbed from the intestinal tract and is often used as a reference for the lower limit of a highly permeable drug.<sup>3,35,50</sup> In an artificial membrane model,  $P_{am}$  of diclofenac, metoprolol and propanolol were  $53.3 \times 10^{-6}$ ,  $5.67 \times 10^{-6}$ , and  $13.7 \times 10^{-6}$  cm/s, respectively.<sup>51</sup>

## Distribution

The apparent volume of distribution is 1.3 L/kg for diclofenac potassium<sup>21</sup> and 1.4 L/kg for diclofenac sodium.<sup>22</sup> Circulating diclofenac is known to be greater than 99% bound to human serum protein, primarily to albumin.<sup>30,52</sup> However, this binding has been described as pharmacokinetically insignificant due to the rapid association–dissociation of diclofenac to albumin, such that the drug readily dissociates and permeates across the vascular membrane to the tissues.<sup>38</sup>

**Table 2.** Excipients<sup>a</sup> Present in Diclofenac<sup>b</sup> IR Soluble Tablets, Dispersable Tablets and Powders for Oral Solution<sup>c</sup> With a Marketing Authorization (MA) in Germany (DE), Denmark (DK), Norway (NO), Spain (ES), Sweden (SE) and United Kingdom (UK)<sup>d</sup>, and the Minimal and Maximal Amount of that Excipient Present Pro Dosage Unit in Solid Oral Drug Products With an MA in the USA<sup>e</sup>

| Excipient                    | Drug Products<br>Containing that Excipient<br>With an MA Granted by<br>the Named Country   | Range Present in<br>Solid Oral Dosage Forms<br>With an MA in the USA (mg) |
|------------------------------|--|---|
| Castor oil hydrogenated      | DE(1–4) DK(5) ES(6) UK (7)   | 0.93–37.6 <sup>f</sup>  |
| Cellulose                    | DE(1–4,8,9) DK(5) ES(6) UK (7)   | 4.6–1385 <sup>f</sup>   |
| Citric acid                  | DE(8,9)  | 2.6–78  |
| Croscarmellose sodium        | DE(1–4) DK(5) ES(6) UK (7)   | 2–180   |
| Crospovidone                 | DE(8,9) ES(10)   | 4.4–792 <sup>f</sup>  |
| Glycerol dibehenate          | DK(11) NO(12) SE (13)  | 5.7–14  |
| Lactose                      | DE(8,9)  | 23–1020 <sup>f</sup>  |
| Magnesium stearate           | DE(8,9) ES(10)   | 0.15–401 <sup>f</sup>   |
| Mannitol                     | DK(11) NO(12) SE (13)  | 33–454  |
| Potassium hydrogen carbonate | DK(11) NO(12) SE (13)  | 12  |
| Povidone                     | DE(1–3) ES(6)  | 0.17–75   |
| Silica                       | DE(1–4,8,9) DK(5) ES(6) UK (7)   | 0.65–99   |
| Sodium starch glycolate      | DE(1–4) DK(5) ES(6) UK (7)   | 2–876 <sup>f</sup>  |
| Starch                       | DE(8,9)  | 0.44–1135 <sup>f</sup>  |
| Talc                         | DE(1–4) DK(5) ES(6) UK (7)   | 0.26–220 <sup>f</sup>   |
| 1.                           | Diclofenac AbZ 50 mg Trinktabletten (Mono) <sup>g</sup>  |   |
| 2.                           | Diclofenac-CT 50 mg Trinktabletten (Mono) <sup>g</sup>   |   |
| 3.                           | Diclofenac-ratiopharm <sup>®</sup> 50 mg Disperstabletten Tabletten zur Herstellung einer Suspension zum Einnehmen (Mono) <sup>g</sup> |   |
| 4.                           | Voltaren <sup>®</sup> Dispers Tabletten (Mono) <sup>g</sup>  |   |
| 5.                           | Voltaren, opløselige tabletter <sup>g</sup>  |   |
| 6.                           | DICLOFENACO RCA 50 mg comprimidos dispersables EFG <sup>g</sup>  |   |
| 7.                           | Voltarol Dispersible Tablets 50 mg <sup>g</sup>  |   |
| 8.                           | Diclac <sup>®</sup> Dispers Tabletten (Mono) <sup>g</sup>  |   |
| 9.                           | Diclo dispers <sup>®</sup> Tabletten zur Herstellung einer Suspension zum Einnehmen (Mono) <sup>g</sup>                                |   |
| 10.                          | DICLOFENACO NORMON 50 mg Comprimidos Dispersables EFG <sup>g</sup>   |   |
| 11.                          | Voltaren Rapid, pulver til oral opløsning <sup>h</sup>   |   |
| 12.                          | CATAFLAM 50 mg dosepulver til mikstur, opløsning <sup>h</sup>  |   |
| 13.                          | Voltaren 50 mg pulver till oral lösning, dospåse <sup>h</sup>  |   |

<sup>a</sup>Colourants, flavors and ingredients present in the printing ink only are not included.

<sup>b</sup>Diclofenac potassium and diclofenac sodium. The salt form present is indicated for each product.

<sup>c</sup>Drug products containing more than one API are excluded.

<sup>d</sup>Sources of data: DE, [www.rote-liste.de](http://www.rote-liste.de) (assessed October 24, 2007); DK, [www.dkma.dk](http://www.dkma.dk) (assessed October 24, 2007); NO, [www.legemiddelverket.no](http://www.legemiddelverket.no) (assessed September 20, 2007); ES, [www.aged.es](http://www.aged.es) (assessed October 24, 2007); SE, [www.lakemedelsverket.se](http://www.lakemedelsverket.se) (assessed October 24, 2007); UK, [www.medicines.org.uk](http://www.medicines.org.uk) (assessed February 7, 2008).

<sup>e</sup>FDA's Inactive Ingredient Database, <http://www.fda.gov/cder/iig/iigfaqweb.htm#purpose> (version date November 1, 2007).

<sup>f</sup>The reported upper range value is unusually high. The authors doubt its correctness.

<sup>g</sup>Contains diclofenac sodium.

<sup>h</sup>Contains diclofenac potassium.

## Metabolism

Diclofenac undergoes extensively hepatic biotransformation involving aromatic hydroxylations and conjugations.<sup>53,54</sup> Five diclofenac metabolites have been identified.<sup>22,41,54</sup> One metabolite has a very weak pharmacological activity.<sup>22</sup>

## Excretion

Approximately 65% of diclofenac is excreted in the urine, largely as metabolites, and 35% in bile as conjugates of unchanged diclofenac and metabolites.<sup>22</sup> Very little drug is eliminated in the unchanged form in urine.<sup>44</sup> The terminal half-life of unchanged diclofenac is approximately 2 h.<sup>22,30</sup>

**Table 3.** Solubility of Diclofenac Sodium from Literature Data<sup>19</sup> and the Corresponding Dose/Solubility (D/S) Ratio's for Three Tablet Strengths

| pH  | Medium           | Solubility (mg/mL) (23 ± 2°C) | D/S <sup>a</sup> (mL) |                    |                    |
|-----|------------------|-------------------------------|-----------------------|--------------------|--------------------|
|     |                  |                               | 12.5 mg               | 25 mg              | 50 mg <sup>b</sup> |
| 1.2 | 0.1 N HCl        | 0.0012                        | 12500 <sup>c</sup>    | 25000 <sup>c</sup> | 50000 <sup>c</sup> |
| 2.0 | 0.01 N HCl       | 0.0017                        | 7353 <sup>c</sup>     | 14706 <sup>c</sup> | 29412 <sup>c</sup> |
| 3.0 | 0.001 N HCl      | 0.28                          | 45                    | 89                 | 179                |
| 4.1 | Acetate buffer   | 0.0033                        | 3788 <sup>c</sup>     | 7576 <sup>c</sup>  | 15152 <sup>c</sup> |
| 4.5 | Acetate buffer   | 0.0036                        | 3472 <sup>c</sup>     | 6944 <sup>c</sup>  | 13889 <sup>c</sup> |
| 5.5 | Acetate buffer   | 0.036                         | 347 <sup>c</sup>      | 694 <sup>c</sup>   | 1389 <sup>c</sup>  |
| 5.8 | Phosphate buffer | 0.14                          | 89                    | 179                | 357 <sup>c</sup>   |
| 6.0 | Phosphate buffer | 0.15                          | 83                    | 167                | 333                |
| 6.8 | Phosphate buffer | 0.67                          | 19                    | 37                 | 75                 |
| 7.0 | Phosphate buffer | 1.36                          | 9                     | 18                 | 37                 |
| 7.4 | Phosphate buffer | 5.15                          | 2                     | 5                  | 10                 |
| 7.8 | Phosphate buffer | 12.00                         | 1                     | 2                  | 4                  |
| 8.0 | Phosphate buffer | 12.14                         | 1                     | 2                  | 4                  |

<sup>a</sup>Critical limit: <250 mL.<sup>2-4</sup>

<sup>b</sup>Highest tablet strength of IR solid oral dosage forms on USA and EU market.

<sup>c</sup>Exceeds critical limit.

## DOSAGE FORM PERFORMANCE

### Excipients and/or Manufacturing Variations

Excipients present in diclofenac sodium and diclofenac potassium IR solid oral drug products with an MA in the US and some European countries are shown in Table 1. These products are “plain” tablets and are intended to be swallowed intact. In Table 2, the same information is shown for IR soluble tablets, dispersible tablets and powders for oral solution. In view of the MAs, it is presumed that these drug products successfully met the *in vivo* BE criteria. Unlike other APIs, diclofenac products were not exempted from *in vivo* BE studies for some time by the German Regulatory Authorities.<sup>55</sup> More-

over, diclofenac is not on the list of except APIs from *in vivo* BE studies by the Dutch Regulatory Authorities.<sup>56</sup>

### In Vivo Bioequivalence

Several studies demonstrated BE among diclofenac potassium IR products.<sup>39,52,57,58</sup> In a randomized, single dose, two-way crossover study in 66 subjects, a 12.5 mg diclofenac potassium tablet formulation was shown to be bioequivalent in terms of log transformed  $C_{max}$ ,  $AUC_{0-t}$  and  $AUC_{0-\infty}$  to its reference, Voltarol Dolo 12.5 mg tablets (Novartis, Basel, Switzerland).<sup>57</sup> Dissolution profiles of test product were reported to be similar to the reference products marketed in various European countries.<sup>57</sup>

**Table 4.** Solubility of Diclofenac Potassium at Room Temperature and the Corresponding Dose/Solubility (D/S) Ratio's for Three Tablet Strengths

| pH  | Medium           | Solubility (mg/mL) <sup>a</sup> | D/S <sup>b</sup> (mL) |                    |                    |
|-----|------------------|---------------------------------|-----------------------|--------------------|--------------------|
|     |                  |                                 | 12.5 mg               | 25 mg              | 50 mg <sup>c</sup> |
| 4.5 | Acetate buffer   | 0.0014 (0.0001)                 | 8929 <sup>d</sup>     | 17857 <sup>d</sup> | 35714 <sup>d</sup> |
| 6.8 | Phosphate buffer | 0.7167 (0.0165)                 | 17                    | 35                 | 70                 |
| 7.4 | Phosphate buffer | 2.341 (0.016)                   | 5                     | 11                 | 21                 |

<sup>a</sup>Between brackets: standard deviation of mean.

<sup>b</sup>Critical limit: <250 mL.<sup>2-4</sup>

<sup>c</sup>Highest tablet strength of IR solid oral dosage forms on USA and EU market.

<sup>d</sup>Exceeds critical limit.



In another single dose study in 24 healthy volunteers, a diclofenac potassium 50 mg sachet formulation containing excipients such as potassium hydrogen carbonate, mannitol, aspartame, saccharin sodium, glyceryl dibehenate, and flavors proved to be bioequivalent to the reference tablet formulation Voltfast in terms of  $AUC_{0-\infty}$ , although  $C_{max}$  was twofold larger from the sachet formulation.<sup>58</sup> No dissolution studies were performed because the test formulation is a powder for oral solution.

Neuvonen<sup>59</sup> reported no significant change in the pharmacokinetics of diclofenac when coadministered with magnesium hydroxide, but this study was carried out with enteric coated tablets and hence of very limited value for IR dosages forms.

### Dissolution and *In Vitro/In Vivo* Correlation

For diclofenac potassium tablets, the USP30 dissolution specification is not less than 80% ( $Q$ ) of the labeled amount to be dissolved within 60 min in 900 mL simulated intestinal fluid (without enzyme) at 50 rpm in the paddle apparatus.<sup>27</sup> The Ph.Eur and the BP do not contain monographs for IR diclofenac tablets. No *in vitro/in vivo* correlations were identified in the literature for diclofenac IR solid oral dosage forms.

## DISCUSSION

### Solubility

Tables 3 and 4 show the dose/solubility ratio ( $D/S$ ) of each salt at pH 6.0 and above to be less than the critical limit of 250 mL for *highly soluble* according to the present BCS Guidances.<sup>2,3,60</sup> The solubility reported by Kincl et al.<sup>29</sup> at pH 3.0 in 0.001 N HCl appears unexplainably high. All other data show diclofenac to be below pH 4.5 (or pH 5.8, depending on the tablet strength) to be not *highly soluble*. Although most solubility data have been collected at room temperature, it is unlikely that solubility values would be much different at 37°C to change the interpretation in terms of the BCS classification.

### Absorption and Permeability

The complete 100% absorption classifies diclofenac as *highly permeable*.<sup>2,3,60</sup> This classification is

supported by *in vitro* data. Some reports indicate that a permeability coefficient of more than  $1 \times 10^{-6}$  cm/s in Caco-2 model is considered to imply high permeability and/or complete absorption.<sup>49,61,62</sup> Others report that a permeability coefficient over  $10 \times 10^{-6}$  cm/s implies high permeability<sup>11</sup> or >70% absorption in humans.<sup>63</sup> Diclofenac exceeds both criteria. The artificial membrane permeability data and the partitioning data further support the classification of diclofenac as being *highly permeable*.

### BCS Classification

According to all Guidances, the data presented above classify diclofenac in BCS Class II.<sup>2-4</sup> Using the disposition characteristics of the API as an estimate for its permeability, Wu and Benet<sup>64</sup> assigned diclofenac to Class II in a Biopharmaceutics Drug Disposition Classification System (BDDCS).

### Risk for Drug Products to be Bioinequivalent

Tables 1 and 2 show excipients and their quantity limits used in diclofenac IR products with MAs in a number of countries. By virtue of their MAs, it may be assumed that these drug products passed *in vivo BE* studies. Hence, it is inferred that none of the excipients tabulated in these tables has had a significant effect on the extent nor the rate of diclofenac absorption. It is worthy of note that some drug products contain sodium lauryl sulfate, which has been reported to improve drug dissolution of poorly soluble drugs.<sup>65</sup> However, it appears that even if there was improved dissolution, sodium lauryl sulfate did not lead to the drug product to be bioinequivalent. It is deduced that these excipients in these reported limits do not cause interactions that result in bioinequivalence for diclofenac.

We conclude that the low solubility of diclofenac at pH values of 4.5 and below does not pose a substantial risk for bioinequivalence. This may be the result of diclofenac high permeability, as well as the dynamic character of the uptake processes.<sup>66</sup>

### Surrogate Techniques for *In vivo* BE Testing

The rate-limiting step in the absorption of diclofenac from a drug product is gastric emptying, disintegration *in vivo* or dissolution *in vivo*. Comparative *in vitro* dissolution testing in

discriminatory media is a sensible technique to detect significant differences in disintegration *in vivo* or dissolution *in vivo* between a test drug product and comparator. *In vitro* dissolution testing in SIF (pH 6.8) without enzyme is suggested by USP and FDA for IR diclofenac potassium drug products as the quality control test.<sup>27,67</sup> SIF without pancreatin and SIF without pancreatin with 1% (w/v) Tween 20 has been suggested as discriminatory dissolution media for diclofenac sodium prolonged release tablets.<sup>68</sup> Dissolution in these media can be considered as discriminatory dissolution test for IR dosage forms. The BCS Guidance prescribes comparative *in vitro* dissolution testing between test and comparator in pH 1.2, 4.5, and 6.8 buffers and also provides criteria for the assessment of dissolution profile similarity.<sup>2-4</sup> In media pH 1.2 and pH 4.5, no dissolution is expected, providing evidence that no dissolution enhancers are present.

Since diclofenac permeability is high, intestinal absorption is not limiting. An excipient interaction with the permeation process is unlikely. This risk of interaction is even lower if the test product contains excipients that are known to exert no such influence, that is, the excipients tabulated in Tables 1 and 2.

### Patient's Risks Associated With Bioinequivalence

Bioinequivalence with respect to AUC can cause subtherapeutic drug level, resulting in low analgesic efficacy, or supra-bioavailability, which may lead to cardiovascular and gastrointestinal side-effect risks. However, diclofenac products are used for non-life-threatening conditions, which require achieving minimal effective plasma concentration. The issue of supra-bioavailability is not critical, as diclofenac is a relatively safe drug with wide therapeutic range.<sup>69,70</sup> Most diclofenac drug products carry a leaflet in which patients are advised to observe and report back any signs or symptoms related to cardiovascular and gastrointestinal events to the physician.

### CONCLUSION

According to the current FDA and EMEA BCS Guidances, only BCS class I APIs are eligible for the biowaiver,<sup>3,60</sup> and diclofenac would not qualify for such a biowaiver. However, the recent WHO Guidance<sup>2</sup> opens a possibility for biowaiving of drug products containing BCS Class II APIs with

weak acidic properties. This viewpoint for highly permeable acidic APIs has been supported for NSAIDs generally.<sup>49</sup> Certain conditions must be fulfilled, such as requirements with respect to *in vitro* dissolution; the excipients should be critically evaluated; and the risk of an incorrect biowaiver decision need to be assessed in terms of public health and risks to individual patients.<sup>2</sup> Diclofenac fulfills these criteria.

The question regarding the acceptability of biowaiving between pharmaceutical alternatives requires further discussion. Pharmaceutical alternatives are drug products containing the same molar amount of the same API, but differing in dosage form (e.g., tablet vs. capsule; "plain" tablet vs. dispersible tablet), or chemical form (e.g., different salts, different esters), delivering the same active moiety by the same route of administration.<sup>2</sup>

In *in vivo* BE testing, different salt forms of the API present in test and comparator are potentially allowed if there is no safety concerns.<sup>60,71</sup> However, in *in vitro* BE testing, a more conservative approach is prudent in granting biowaivers between different salt forms of an API. Moreover, these two salts sometimes have different therapeutic indications, as diclofenac potassium is sometimes claimed to be absorbed faster than the sodium salt and hence recommended for the treatments that need short onset of action. Hence, we recommend against a biowaiver when the test and comparator do not contain the same salt form of diclofenac.

The FDA, EMEA, and WHO Guidance provide some possibility for *in vivo* BE testing between pharmaceutical alternatives that differ in dosage form, such as IR tablets versus IR capsules.<sup>60,71</sup> Available diclofenac IR solid oral dosage forms include plain tablets, dispersible tablets, and powders for solution which are different dosage forms. As above, a more conservative approach is prudent in granting biowaivers between different solid oral dosage forms of an API. We recommend against a biowaiver when the test and comparator do not contain the same dosage form of diclofenac.

In summary, a biowaiver for IR solid oral dosage forms of diclofenac potassium and diclofenac sodium are scientifically justified, provided that: (a) test and comparator contain the same diclofenac salt; (b) the dosage form of the test and comparator is identical; (c) the test product contains only excipients present in diclofenac drug products approved in ICH or associated

countries in the same dosage form, such as those shown in Tables 1 and 2, in amounts that are usual for that dosage form; (d) test drug product and comparator dissolve 85% in 30 min or less in 900 mL buffer pH 6.8, using the paddle apparatus at 75 rpm or the basket apparatus at 100 rpm; and (e) test product and comparator show dissolution profile similarity in pH 1.2, 4.5, and 6.8.

## ACKNOWLEDGMENTS

Supported in part by a grant from AstraZeneca Pharmaceuticals. Kik Groot, RIVM, is acknowledged for producing Tables 1 and 2.

## REFERENCES

- Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Moller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. *J Pharm Sci* 93:1945–1956.
- WHO. 2006. Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms. Technical Report Series No. 937, 40th Report, Annex 8 of WHO Expert committee on specifications for pharmaceutical preparations. Available from URL [http://healthtech.who.int/pq/info\\_general/documents/TRS937/WHO\\_TRS\\_937\\_\\_annex8\\_eng.pdf](http://healthtech.who.int/pq/info_general/documents/TRS937/WHO_TRS_937__annex8_eng.pdf).
- U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Available from URL <http://www.fda.gov/cder/guidance/3618fnl.pdf>.
- Committee for Proprietary Medicinal Products (CPMP). 2007. Concept paper on BCS-based biowaiver. Available from URL <http://www.emea.europa.eu/pdfs/human/ewp/21303507en.pdf>
- Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). *J Pharm Sci* 95:4–14.
- Granero GE, Longhi MR, Becker C, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. in press. Biowaiver monographs for immediate release solid oral dosage forms: Acetazolamide. *J Pharm Sci*.
- Arnal J, Gonzalez-Alvarez I, Bermejo M, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky SA, Dressman JB, Barends DM. in press. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. *J Pharm Sci*.
- Manzo RH, Olivera ME, Amidon GL, Shah VP, Dressman JB, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline hydrochloride. *J Pharm Sci* 95:966–973.
- Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. *J Pharm Sci* 94:1389–1395.
- Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. *J Pharm Sci* 95:974–984.
- Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride. *J Pharm Sci* 97:1350–1360.
- Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. *J Pharm Sci* 94:2121–2131.
- Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid. *J Pharm Sci* 96:522–531.
- Vogt M, Derendorf H, Kramer J, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone. *J Pharm Sci* 96:27–37.
- Vogt M, Derendorf H, Kramer J, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisone. *J Pharm Sci* 96:1480–1489.
- Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky SA, Barends DM. in press. Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide. *J Pharm Sci*.
- Kortejarvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid

- oral dosage forms: Ranitidine hydrochloride. *J Pharm Sci* 94:1617–1625.
18. WHO. 2005. Model list of essential medicines, 14th edition. Available from URL [http://whqlibdoc.who.int/hq/2005/a87017\\_eng.pdf](http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf)
  19. Riess W, Stierlin H, Degen P, Faigle JW, Gerardin A, Moppert J, Sallmann A, Schmid K, Schweizer A, Sulc M, Theobald W, Wagner J. 1978. Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. *Scand J Rheumatol Suppl* 22:17–29.
  20. Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K. 2003. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. *Clin Pharmacol Ther* 74:222–235.
  21. Novartis. 2005. Prescribing information of Cataflam. Available from URL <http://www.pharma.us.novartis.com/product/pi/pdf/Cataflam.pdf>
  22. Novartis. 2006. Prescribing information of Voltaren. Available from URL <http://www.pharma.us.novartis.com/product/pi/pdf/Voltaren.pdf>
  23. Brundig P, Börner RH, Haerting R, Janitzky V, Schlichter A. 1990. Glycose aminoglycane excretion and concentration in the urine of patients with frequently recurrent calcium-oxalate lithiasis prior to and following Diclofenac-Na therapy. *Urol Res* 18:21–24.
  24. Maggi CA, Lualdi P, Mautone G. 1990. Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man. *Eur J Clin Pharmacol* 38:207–208.
  25. Fini A, Garuti M, Fazio G, Alvarez-Fuentes J, Holgado MA. 2001. Diclofenac salts. I. Fractal and thermal analysis of sodium and potassium diclofenac salts. *J Pharm Sci* 90:2049–2057.
  26. Bartolomei M, Bertocchi P, Antoniella E, Rodomonte A. 2006. Physico-chemical characterization and intrinsic dissolution studies of a new hydrate form of diclofenac sodium: Comparison with anhydrous form. *J Pharm Biomed Anal* 40:1105–1113.
  27. USP 30-NF 25. 2007. The United States Pharmacopoeia-The National Formulary. Rockville, MD, 20852: The United States Pharmacopoeial Convention, Inc.
  28. EP. 2008. The European Pharmacopoeia. 6th edition. The European Directorate for the quality of medicines & Health Care.
  29. Kincl M, Meleh M, Veber M, Vrečer F. 2004. Study of physicochemical parameters affecting the release of diclofenac sodium from lipophilic matrix tablets. *Acta Chim Slov* 51:409–425.
  30. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. 1979. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. *J Clin Pharmacol* 16:405–410.
  31. Khazaeinia T, Jamali F. 2003. A comparison of gastrointestinal permeability induced by diclofenac phospholipid complex with diclofenac acid and its sodium salt. *J Pharm Pharmaceut Sci* 6:352–359.
  32. Hendriksen BA, Sanchez Felix MV, Bolger MB. 2003. The composite solubility versus pH profile and its role in intestinal absorption prediction. *AAPS Pharm Sci* 5:1–15.
  33. Kourounakis AP, Galanakis D, Tsiakitzis K, Rekka EA, Kourounakis PN. 1999. Synthesis and pharmacological evaluation of novel derivatives of anti-inflammatory drugs with increased antioxidant and anti-inflammatory activities. *Drug Dev Res* 47:9–16.
  34. Summerfield SG, Stevens AJ, Cutler L, Osuna M, Hammond B, Tang S, Hersey A, Spalding DJ, Jeffrey P. 2006. Improving the in vitro prediction of in vivo central nervous system penetration: Integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. *J Pharmacol Exp Ther* 316:1282–1290.
  35. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. *Mol Pharm* 1:85–96.
  36. O'Connor KM, Corrigan OI. 2001. Preparation and characterization of a range of diclofenac salts. *Int J Pharm* 226:163–179.
  37. Tantishaiyakul V. 2004. Prediction of aqueous solubility of organic salts of diclofenac using PLS and molecular modeling. *Int J Pharm* 275:133–139.
  38. Moore N. 2007. Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: A review of its pharmacology, clinical efficacy and safety. *Clin Drug Invest* 27:163–195.
  39. Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, Szelenyi I, Brune K, Werner U. 2005. Bioavailability of diclofenac potassium at low doses. *Br J Clin Pharmacol* 59:80–84.
  40. Van Dermarel CD, Anderson BJ, Romsing J, Jacoz-Aigrain E, Tibboel D. 2004. Diclofenac and metabolite pharmacokinetics in children. *Pediatr Anesth* 14:443–451.
  41. John VA. 1979. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. *Rheumatol Rehabil Suppl* 2: 22–37.
  42. Lotsch J, Kettenmann B, Renner B, Drover D, Brune K, Geisslinger G, Kobal G. 2000. Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: Relation to pharmacodynamics in an experimental pain model. *Pharm Res* 17: 77–84.
  43. Kendall MJ, Thornhill DP, Willis JV. 1979. Factors affecting the pharmacokinetics of diclofenac sodium (Voltarol). *Rheumatol Rehabil Suppl* 2: 38–46.

44. Davies NM, Anderson KE. 1997. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. *Clin Pharmacokinet* 33:184–213.
45. Terhaag B, Hoffmann A, Barkworth M, Vens-Cappell B. 2000. Bioavailability of a new effervescent tablet of diclofenac. *Int J Clin Pharmacol Ther* 38:546–551.
46. Idkaidek NM, Amidon GL, Smith DE, Najib NM, Hassan MM. 1998. Determination of the population pharmacokinetic parameters of sustained-release and enteric-coated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. *Biopharm Drug Dispos* 99:169–174.
47. Willis JV, Kendall MJ, Jack DB. 1981. The influence of food on the absorption of diclofenac after single and multiple oral doses. *Eur J Clin Pharmacol* 19:33–37.
48. Terhaag B, Gramatte T, Hrdlcka P, Richter K, Feller K. 1991. The influence of food on the absorption of diclofenac as a pure substance. *Int J Clin Pharmacol Ther Toxicol* 29:418–421.
49. Yazdanian M, Briggs K, Jankovsky C, Hawi A. 2004. The “high solubility” definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. *Pharm Res* 21:293–299.
50. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. 2006. A provisional biopharmaceutical classification of the top 200 oral drug product in the United States, Great Britain, Spain and Japan. *Mol Pharmaceutics* 3:631–643.
51. Obata K, Sugano K, Machida M, Aso Y. 2004. Biopharmaceutics classification by high throughput solubility assay and PAMPA. *Drug Dev Ind Pharm* 30:181–185.
52. Novartis. 2001. Prescribing information of Cataflam and Voltaren. Available from URL <http://www.fda.gov/cder/foi/label/2001/20254s2lbl.pdf>
53. Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J. 1999. Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways. *Biochem Pharmacol* 58:787–796.
54. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmüller J. 2003. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: No relationship to the CYP2C9 genetic polymorphism in humans. *Br J Clin Pharmacol* 55: 51–61.
55. Gleiter CH, Klotz U, Kuhlmann K, Blume H, Stanislaus F, Harder S, Paulus H, Poethko-Muller C, Holz-Slomeczyk M. 1998. When are bioavailability studies required? A German proposal. *J Clin Pharmacol* 38:904–911.
56. <http://www.cbg-meb.nl/CBG/nl/people/geneesmiddelen/allergie-informatie/default.htm#Bio-equivalentieonderzoek>.
57. Medicines and Healthcare Products Regulatory Agency (MHRA). 2007. Diclofenac potassium 12.5 mg tablets PL 24668/0001. Available from URL [http://www.mhra.gov.uk/home/idcplg?IdcService=SS\\_GET\\_PAGE&nodeId=5](http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=5).
58. Marzo A, Bo LD, Vergaf F, Ceppimontin N, Abbonatig G, Aleottitettamanti R, Crivellif F, Uhr MR, Ismaili S. 2000. Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. *Arzneim Forsch* 50:43–47.
59. Neuvonen P. 1991. The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac. *Br J Clin Pharmacol* 31:263–266.
60. Committee for Proprietary Medicinal Products (CPMP). 2001. Note for guidance on the investigation of bioavailability and bioequivalence. Available from URL <http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf>
61. Yazdanian M, Glynn SL, Wright JL, Hawi A. 1998. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. *Pharm Res* 15:1490–1494.
62. Artursson P, Karlsson J. 1991. Correlation between oral drug permeability coefficients in human intestinal epithelial (Caco-2) cells. *Biochem Biophys Res Commun* 175:880–885.
63. Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—Fact or myth. *Pharm Res* 14:763–766.
64. Wu C, Benet LZ. 2005. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. *Pharm Res* 22:11–23.
65. Balakrishnan A, Rege BD, Amidon GL, Polli JE. 2004. Surfactant-mediated dissolution: Contributions of solubility enhancement and relatively low micelle diffusivity. *J Pharm Sci* 93:2064–2075.
66. Rinaki E, Dokoumetzidis A, Valsami G, Macheras P. 2004. Identification of biowaivers among class II drugs: Theoretical justification and practical examples. *Pharm Res* 21:1567–1572.
67. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2006. Dissolution Method for Drug Products. Available from URL <http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm?c=1>.
68. Bertochi P, Antoniella E, Valvo L, Alimonti S, Memoli A. 2005. Diclofenac sodium multisource prolonged release tablets—a comparative study on the dissolution profiles. *J Pharm Biomed Anal* 37:679–685.
69. Menasse R, Hedwall PR, Kraetz J, Pericin C, Riesterer L, Sallmann A, Ziel R, Jaques R. 1978. Pharmacological properties of diclofenac sodium and its metabolites. *Scand J Rheumatol Suppl* 22:5–16.
70. Poli A, Moreno RA, Ribeiro W, Dias HB, Moreno HJ, Muscara MN, De Nucci G. 1996. Influence of gastric

acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers. Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers. *Int J Clin Pharmacol Ther* 34:76-79.

71. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2003. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Available from URL <http://www.fda.gov/cder/guidance/5356fml.pdf>